Form 4: Cryo-Cell International CFO Acquires 10,000 Stock Options
SEC Form 4 Filing
Jill M. Taymans, CFO of Cryo-Cell International, reports the acquisition of 10,000 stock options.
Summary
- Jill M. Taymans, VP Finance and CFO of Cryo-Cell International Inc. (CCEL), filed a Form 4 on January 23, 2025, reporting a transaction.
- The transaction involved the acquisition of 10,000 stock options with an exercise price of $7.35 on January 21, 2025.
- These options vest in three tranches: 1/3 upon issuance, 1/3 on January 21, 2026, and 1/3 on January 21, 2027.
- The options expire on January 21, 2030.
- Following the reported transaction, Ms. Taymans beneficially owns 45,396 shares of common stock directly.
- She also holds derivative securities including 7,500 stock options exercisable at $3.10 (vested since June 2, 2019), 7,000 stock options exercisable at $8.00 (vesting from September 23, 2020), 20,000 stock options exercisable at $4.62 (vested since January 13, 2023), and 10,000 stock options exercisable at $5.88 (vesting from December 22, 2023).
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports an insider transaction, which can be viewed as slightly positive as it shows the CFO's continued investment in the company, but it's not a strong indicator of future performance.
Positives
- The acquisition of stock options by the CFO could be interpreted as a sign of confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions and is common for publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.
Stakeholder Impact
- Shareholders may view the CFO's stock option acquisition as a positive signal, indicating confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 06/02/2019 | Date from which 7,500 stock options with an exercise price of $3.10 became exercisable. |
| 09/23/2020 | Date from which 7,000 stock options with an exercise price of $8.00 began vesting. |
| 01/13/2023 | Date from which 20,000 stock options with an exercise price of $4.62 became exercisable. |
| 12/22/2023 | Date from which 10,000 stock options with an exercise price of $5.88 began vesting. |
| 01/21/2025 | Date of the reported transaction: acquisition of 10,000 stock options with an exercise price of $7.35; also the date from which these options begin vesting. |
| 01/23/2025 | Date of Form 4 filing. |
| 01/21/2026 | Date of second vesting tranche for the 10,000 stock options acquired on January 21, 2025. |
| 01/21/2027 | Date of final vesting tranche for the 10,000 stock options acquired on January 21, 2025. |
| 01/21/2030 | Expiration date of the 10,000 stock options acquired on January 21, 2025. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.